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ABSTRACT: Colorectal cancer is one of the most signiﬁcant
types of cancer, ranking second in the world’s mortality cases. As
colorectal cancer is often diagnosed at a late stage of disease
progression, eﬀective treatments are necessary. Therefore, radiotherapy has become a fundamental approach in the treatment of
colorectal cancer, especially those based on the use of 177Lu. A
potential approach to meet this challenge is the use of
nanotechnology through the development of radionuclide-based
nanomaterials. In this work, we investigated a SiO2-derived class of
nanomaterials formed by the insertion of the coordination
complex, based on Eu3+ and pyrimidine-2,6-dicarboxylic acid
(DPA), into nanoparticles of amino-functionalized mesoporous
silica (EuDPA/SiO2−NH2). The properties of the EuDPA/SiO2−NH2 nanoparticles were initially investigated by SEM, FT-IR,
TGA, and luminescence. The cellular uptake of EuDPA/SiO2−NH2 nanoparticles into HT-29 cells was conﬁrmed by ﬂuorescence
microscopy. Radioactivity was incorporated into the EuDPA/SiO2−NH2 nanoparticles by replacing a tracer quantity of Eu3+ sites
with the lanthanide element 177Lu, which resulted in the composition of a dual-modality probe for both SPECT imaging and tumor
radiotherapy. Analysis of 177Lu loading into EuDPA/SiO2−NH2 particles showed eﬃcient incorporation, up to 93% radioactivity
into the ﬁnal compound. The imaging potential of the 177Lu−EuDPA/SiO2−NH2 nanoparticles was investigated by SPECT/CT
imaging, a subcutaneous HT-29 mouse model of colorectal cancer. Image analysis showed that tumor localization was maintained
after intratumoral administration for up to 48 h. To evaluate the therapeutic potential of 177Lu−EuDPA/SiO2−NH2 nanoparticles,
HT-29 xenografts were treated in vivo by direct intratumoral injection. Compared with control (PBS) treatment or treatment with
unlabeled EuDPA/SiO2−NH2 nanoparticles, the treatment with 177Lu−EuDPA/SiO2−NH2 nanoparticles resulted in a signiﬁcantly
reduced tumor growth. Together, the results of this study results indicate that 177Lu−EuDPA/SiO2−NH2 is a promising agent for
further development in SPECT imaging and clinical treatment of colorectal cancer.
KEYWORDS: colorectal cancer, coordination compound, dipicolinic acid, HT-29, lutetium-177, nanoparticle photoluminescence,
radiotherapy, SPECT imaging
β-emitting radioisotopes, including 131I, 90Y, 177Lu, and 186Re,
have received considerable attention in recent years for particle
radiation therapy because they are readily available, have
favorable emission characteristics, and are accessible to
straightforward radiochemistry technologies.
In particular, 177Lu (half-life 6.7 days) has emerged as an
ideal dual-modality radionuclide. In essence, it is a medium-

1. INTRODUCTION
Colorectal cancer is one of the most signiﬁcant health issues
worldwide; it is estimated that colorectal cancer is the third
most common cancer, with an estimated 1.8 million new cases
diagnosed each year.1 Because colorectal cancer is often
diagnosed at a late stage of disease progression, about 900000
individuals die annually globally, making this malignancy the
second leading cause of cancer death.1 Thus, the development
of eﬀective treatments is sorely needed.
In addition to surgery and chemotherapy, radiotherapy has
become a mainstay approach for treating colon cancer. There
are two diﬀerent approaches to radiotherapy:2 (1) using
electromagnetic radiation (i.e., ionizing radiation typically used
for external beam radiotherapy) or (2) particle radiation (i.e.,
radioisotopes emitting α, β−, or Auger electron particles). The
© 2020 American Chemical Society
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Lu−EuDPA/SiO2−NH2 hybrid nanoparticle synthesis.

177

energy β-emitter (at 490 keV) for radiotherapy application,
and it emits low-energy γ-rays (at 208 and 113 keV), which are
useful for diagnostic imaging by SPECT (single photon
emission computerized tomography).3
Beta particles emitted from 177Lu decay travel relatively
short distances in tissue (1−2 mm).4 In locoregional
applications, the resulting energy can be absorbed by the
disease target sites, killing the cancer cells without having
damaging eﬀects on surrounding normal tissues.5 There is a
need to improve further the therapeutic eﬃcacy of radiotherapy using radionuclides such as 177Lu by identifying
alternative approaches for delivering these agents to a tumor
site. One potential approach to address this challenge is to
utilize nanotechnology for targeted delivery through the
development of multifunctional nanomaterials.6
Radiolabeled nanoparticles represent a class of agents that
has been recognized to have enormous potential for clinical
oncology applications.7 Recent trends in nuclear medicine are
aimed at exploiting these materials in a multifunctional
approach, in which these systems are engineered with
combined properties of molecular detection and therapeutic
capabilities, known as theranostics.8 The success of this
approach depends on the property choice of radionuclides
for incorporation into a nanoparticle platform. For example, γemitters with energy in the 150 keV range have been useful in
the context of SPECT imaging, while those radioisotopes that
are also β-emitters are capable of producing therapeutic
cellular damage and cell death.7,8
Currently, the choice of these nanomaterials in colorectal
cancer therapy has grown considerably,9 which can be
represented by inorganic compounds (i.e., carbon nanotubes,10
silica nanoparticles,11 gold nanoparticles,12 magnetic nanoparticles,13 quantum dots,14 etc.) and organic compounds (i.e.,
natural compounds,15,16 polymeric micelles,17 liposomes,18
dendrimers,19 etc.). As shown in Figure 1, we developed a
novel class of nanomaterials, in which lanthanide coordination
complexes of Eu3+ and pyridine-2,6-dicarboxylic acid (H2DPA)
were coupled into amino-functionalized mesoporous silica
nanoparticles (EuDPA/SiO2−NH2), and 177LuCl3 was incorporated.
Silica nanoparticles have been exploited for numerous
biomedical applications based on their biocompatibility, low
toxicity, and capability of precise control over nanostructure
synthesis.20 In addition, surface modiﬁcations of silica
nanoparticles are possible, allowing for modulation of drug
loading, pharmacokinetics, and targeted delivery.21 We
examined the characteristics of the EuDPA/SiO2−NH2
nanoparticles by SEM, FT-IR, TGA, and luminescence to
deﬁne their chemical, morphological, and optical properties for
the application of interest. We also determined the cellular
uptake of EuDPA/SiO2−NH2 nanoparticles into the human
HT-29 colon cancer cell line.
Radioactivity was also incorporated into the EuDPA/SiO2−
NH2 nanoparticles by adding a tracer amount of the lanthanide
element 177Lu into the Eu3+ sites of the nanostructure, resulting

in the composition of a dual-modality probe capable of both
SPECT imaging and tumor radiotherapy. After determining
the eﬃciency of 177Lu incorporation into the EuDPA/SiO2−
NH2 nanoparticles, we performed SPECT/CT imaging and
biodistribution studies to assess uptake in vivo in mice. Finally,
the antitumor eﬃcacy of 177Lu−EuDPA/SiO2−NH2 nanoparticle radiotherapy treatment was evaluated by using an HT29 tumor xenograft mouse model. Together, these results
demonstrate the potential use of 177Lu−EuDPA/SiO2−NH2 as
a colon cancer therapeutic agent and support further in vitro
and in vivo investigations.

2. MATERIALS AND METHODS
2.1. Reagents. All experimental procedures were performed by
using analytical grade reagents purchased commercially from SigmaAldrich (St. Louis, MO).
2.2. Synthesis of the EuDPA Coordination Compound. The
EuDPA complex was synthesized by using the method described by
Tao et al.22 For this approach, 0.343 g of H2DPA (2 mmol) was
added to 20 mL of ethanol under stirring conditions. After that, 1 M
NaOH(aq) portions were added dropwise until the solution reached
pH = 7. Finally, 0.366 g of EuCl3·6H2O (1 mmol) was dissolved in
another 20 mL of ethanol. A precipitate was produced by the
dropwise addition of the EuCl3·6H2O in ethanol. Subsequently, the
precipitate was ﬁltered, washed with ethanol, and stored in a clean,
dry ﬂask.
2.3. Synthesis of EuDPA/SiO2−NH2 Hybrid Nanoparticles.
For the synthesis of the hybrid nanoparticles, an adaptation of the
Stober sol−gel method23,24 was used to incorporate the EuDPA
complex into the matrix of silica nanoparticles. This methodology
consists of mixing 30 μL/0.09 mmol of EuDPA(aq) (2 mg/mL), 20
μL of NH4OH, and 27 μL of tetraethyl orthosilicate (TEOS) for 4 h
under agitation at ambient temperature. Afterward, the mixture was
added to 5.2 μL of 3-aminopropyltriethoxysilane (APTES), and the
mixture was stirred for another 1 h. Finally, the resulting material was
transferred to a 15 mL centrifuge tube and centrifuged for 10 min at
8000 rpm. The centrifugation procedure was repeated three more
times by using 1 mL of ultrapure water to wash the material.
2.4. Synthesis of Lu0.5−Eu0.5DPA/SiO2−NH2 Hybrid Nanoparticles. The same protocol used for the synthesis of EuDPA/
SiO2−NH2 was repeated, altering only the addition of 0.045 mmol of
EuDPA(aq) and 0.045 mmol of LuCl3·6H2O(aq) in a volume of 30
μL of water instead of only 0.09 mmol of EuDPA(aq) as previously
described.
2.5. Synthesis of 177Lu−EuDPA/SiO2−NH2 Hybrid Nanoparticles. A mixture was prepared from EuDPA(aq) (2 mg/mL), 5
μL of 177LuCl3 (37−111 MBq; 1−3 mCi), 20 μL of NH4OH, and 10
μL of TEOS, which was stirred for 4 h under stirring at ambient
temperature. Afterward, 5.2 μL of APTES was added, and the mixture
was stirred for an additional 1 h. Finally, the material was transferred
to a 1.5 mL microcentrifuge tube and centrifuged for 10 min at 8000
rpm. The centrifugation procedure was repeated three more times by
using 1 mL of water to wash the material, and the radioactivity of the
supernatant and the solid material obtained after centrifugation was
recorded. After the washing procedure, the 177Lu−EuDPA/SiO2−
NH2 product was obtained as a white solid.
2.6. Nanoparticle Characterization. Fourier transform infrared
(FT-IR) spectroscopy was measured at 4000−650 cm−1 on a Bruker
spectrometer (model Tensor 27) equipped with a Pike single-bounce
diamond/ZnSe ATR cell. Scanning electron microscopy (SEM)
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plates at a density of 5 × 103 per well. After 24 h, the cells were
treated with 10, 100, and 1000 μg/mL of the EuDPA/SiO2−NH2
nanoparticle preparation for an additional 24 h. As a positive control
for cytotoxicity, cells were treated with doxorubicin at 1.34 μM, a
concentration representing ∼2× the reported IC50 in HT-29 cells.28
As a negative control, cells were treated with vehicle (PBS) alone. The
cells were treated at each concentration by using eight replicate wells
for 24, 48, and 96 h. At each time point, the plates were subjected to
the following treatment: 50 μL of XTT detection solution (a 1:50
ratio of electron coupling solution to XTT reagent) was added to each
well containing 200 μL of medium. After 2 h incubation at 37 °C, the
optical density (OD) of each well at 595 nm was measured by using a
SpectraMax 190 plate reader (Molecular Devices, San Jose, CA).
2.10. Uptake of 177Lu−EuDPA/SiO2−NH2 Nanoparticles. The
time course of uptake of 177Lu−EuDPA/SiO2−NH2 nanoparticles
into HT-29 cells was determined by gamma scintillation counting
using a model CRC-55tx dose calibrator/well counter (Capintec,
Florham Park, NJ). The HT-29 cells were initially plated for 24 h in
35 mm dishes at a density of 1.5 × 105 per well in DMEM medium
supplemented with 10% fetal bovine serum, 50 U/mL penicillin, and
50 mg/mL streptomycin. After 24 h, the medium was removed, and
the cells were treated by the addition of 4081 MBq (110.3 mCi)
177
Lu−EuDPA/SiO2−NH2 in 1.0 mL of medium. At each time point
after the addition, the cells were harvested by trypsinization, washed
twice with PBS, and counted. The uptake of increasing doses of
177
Lu−EuDPA/SiO2−NH2 nanoparticles into HT-29 cells was also
determined by gamma scintillation counting. The HT-29 cells were
initially plated for 24 h in 35 mm dishes at a density of 1.5 × 105 per
well in DMEM medium. After 24 h, the medium was removed, and
the cells were treated with increasing amounts of 177Lu−EuDPA/
SiO2−NH2 nanoparticles at 6.52, 13.93, 30, 57.7, 113.2, and 224 mCi
in 1.0 mL of medium. At 24 h after the addition, the cells were
harvested by trypsinization and washed twice with PBS, and the cell
pellets were counted. The uptake percentage was calculated as the
amount of radioactivity associated with the cell pellet divided by the
total radioactivity of the cell sample and medium.
2.11. SPECT Imaging. HT-29 tumors were established by
subcutaneous injection of 0.2 mL into the right ﬂanks of six mice at
a concentration of 0.5 × 108 cells/mL resuspended in a 1:1 mixture of
PBS and Matrigel extracellular matrix preparation (Corning, Oneonta,
NY). On day 17, after initial HT-29 injection, the mice were injected
intratumorally with 37 MBq (1.0 mCi) of 177Lu−EuDPA/SiO2−NH2
nanoparticles in 100 μL of PBS, and image acquisition was started at
60 min afterward. Similarly, three mice were injected with ∼37 MBq
(1.0 mCi) of 177LuCl3 in 100 μL of PBS. The animals were
anesthetized with isoﬂurane and ﬁxed in a prone position on the bed
and center of rotation relative to the gantry of a dedicated small
animal SPECT/CT system (TriFoil Imaging, Northridge, CA). After
60 min, 3D SPECT imaging was performed in a step-and-shoot
manner using the following acquisition parameters: 64 projections, 30
s/projection (35 min image acquisition), with a 208 keV photopeak
±10% window. SPECT 3D reconstruction was performed by using
Avizo 9.0.1 software (Thermo Fisher Scientiﬁc, Waltham, MA).
Immediately after SPECT imaging was performed, CT images were
acquired by using the same coordinates as SPECT with 256
projections and 1024 × 1024 projection matrix size and a voltage
of 60 kV; reconstructions were performed by using ﬁltered backprojections.
2.12. HT-29 Xenograft Mouse Model. Female 3−6 week old
athymic nude mice (Envigo RMS, Indianapolis, IN) were used for all
in vivo studies. All animal experiments were performed in compliance
with the Institutional Animal Care and Use Committee (IACUC)
guidelines of Louisiana State University, through which humane care
of animals was ensured. A colorectal tumor xenograft model was
established by subcutaneous injection of 0.2 mL of HT-29 cells into
the right ﬂanks of 15 mice at a concentration of 5 × 107 cells/mL
resuspended in a 1:1 mixture of PBS and Matrigel extracellular matrix
preparation (Corning, Oneonta, NY). On day 5, after initial HT-29
injection, the mice were randomized into three groups of ﬁve mice,

images were acquired on a low-vacuum scanning electron microscope
(JEOL JSM-6610LV) coupled with an energy dispersive X-ray
spectrometer (EDS). EDS analysis was obtained with an angle of
45°. Transmission electron microscopy (TEM) images were obtained
on a CCD camera coupled FEI microscope (model Morgagni 268 D),
with an acceleration voltage 40−100 kV, point resolution 0.45 nm,
line resolution 0.34 nm, and magniﬁcation up to 180000×. The
dynamic light scattering (DLS) analysis was performed on a Microtrac
Zeta Trac 150 particle counter (model/series: S3000/S3500). The
thermogravimetric (TGA) analyses were performed by using a
Shimadzu thermal analyzer (model DTG-60/60H) in atmospheric air.
The photoluminescence properties were investigated using a
Fluorolog-3 spectroﬂuorometer (model FL3-22TAU3; Jobin-Yvon,
Edison, NJ) equipped with a continuous 450 W xenon lamp and UV
xenon ﬂash tube for excitation and a double-grating monochromator
in the excitation and emission positions. The emission spectra were
corrected for the wavelength-dependent response of the detection
system. A silicon photodiode reference detector was used to monitor
and compensate for the variation in the xenon lamp output by using
typical correction spectra provided by the manufacturer. The
experimental coeﬃcients of spontaneous emission, A0J, are obtained
according to the relation
ij I0J yzji ν yz
A 0J = A 01jjj zzzjjjj 01 zzzz
j I01 zj ν0J z
k {k {

(1)

where I01 and I0J are the integrated intensities of the 5D0 → 7F1 and
D0 → 7FJ transitions (J = 0, 2, 3, and 4) with ν01 and ν0J energy
barycenters, respectively. The coeﬃcient of emission spontaneous, A01
in eq 1, is given by the expression A01 = 0.31 × 10−11(n)3(ν01)3, and
its value is estimated to be 50 s−1.25
The emission quantum eﬃciency (η) was calculated according to
eq 2
5

η=

A rad
× 100
A rad + A nrad

Article

(2)

where Arad is the radiative decay rate obtained by summing over the
experimental coeﬃcients of spontaneous emission A0J for each 5D0 →
7
FJ (J = 0−4) transition. The total radiative decay rate (Atotal) is given
by the relation Atotal = τ−1, where τ is the lifetime for the radiative
decay associated with the 5D0 → 7F2 transition. Finally, the
nonradiative decay rate (Anrad) was determined by the diﬀerence
Anrad = Atotal − Arad.26,27
2.7. Cell Culture. The human colon adenocarcinoma cell line,
HT-29, was obtained from the American Type Culture Collection
(Manassas, VA) and grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 50 U/mL
penicillin, and 50 mg/mL streptomycin. The cultured HT-29 cells
were maintained in 5% CO2 at 37 °C under a humidiﬁed atmosphere
condition.
2.8. Confocal Microscopy. The HT-29 cells were plated into 35
mm glass-bottom cell culture dishes (Thermo Fisher Scientiﬁc,
Waltham, MA) at a density of 1.5 × 105 per dish for confocal
microscopy. After 24 h, the cells were treated with 10, 100, and 1000
μg/mL of each nanoparticle preparation for an additional 24 h.
Subsequently, the medium was removed, and the cells were incubated
for 10 min with 1 mL of phosphate-buﬀered saline (PBS) containing
5 μL of Hoechst 33342 dye. Subsequently, the cells were washed
three times with 1 mL of PBS and visualized by confocal microscopy
using a Leica SP8 confocal microscope platform with a white light
laser source.
2.9. XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) Cytotoxicity Assay. The cell cytotoxicity after treatment with EuDPA/SiO2−NH2 nanoparticles was
determined by using an XTT assay (Cell Signaling Technology,
Danvers, MA). The XTT assay is based on the reduction of a colorless
tetrazolium salt to a colored formazan product due to the activity of
mitochondrial dehydrogenases in the mitochondria of living cells. The
HT-29 cells were initially plated for 24 h in 96-well tissue culture
8693

https://dx.doi.org/10.1021/acsanm.0c01427
ACS Appl. Nano Mater. 2020, 3, 8691−8701

ACS Applied Nano Materials

www.acsanm.org

Article

Figure 2. Representative images obtained by scanning electron microscopy (A, B) and transmission electron microscopy (C, D) of EuDPA/SiO2−
NH2 nanoparticles.
and the tumor dimensions of each mouse were measured with digital
calipers. Tumor volumes were calculated employing eq 3
V = D × d 2 × 0.52

3. RESULTS AND DISCUSSION
3.1. Morphology and Chemical Evaluation. TEM and
SEM images were acquired to characterize the synthesis of the
EuDPA/SiO2−NH2 nanoparticles and elucidate the morphological properties of the product. SEM images obtained at
diﬀerent magniﬁcations (Figures 2A and 2C) revealed the
formation of small blocks with irregular morphology. The
results of TEM (Figures 2B and 2D) showed that the EuDPA/
SiO2−NH2 product was formed by small particles with sizes of
<20 nm. It is important to emphasize that the particles had a
morphology similar to those published in the literature.29−31
These results conﬁrmed the material composition as a
nanocarrier and strengthened the use of the system proposed
in this work.
Particle size analysis was also performed by using the DLS
technique for the silica nanoparticles (without EuDPA) and
the EuDPA/SiO2−NH2 compound, as shown in Figures S1A
and S1B, respectively. This analysis revealed that the silica
particles had an average particle size of 21.7 nm, while the
EuDPA/SiO2−NH2 particles had an average particle size equal
to 63.3 nm. These results indicate that the EuDPA/SiO2−NH2
compound was maintained at the nanoscale, and the insertion
of the EuDPA complex into the nanoparticle structure favored
an increase in particle size.
A Lu0.5−Eu0.5DPA/SiO2−NH2 nanoparticle formulation was
synthesized and characterized by transmission electron
microscopy (Figures 3A−C) to determine whether there was
a perturbation of nanoparticles by the occupation of lutetium

(3)

where V is the tumor volume, D is the largest tumor dimension, and d
is the smallest tumor dimension. After 17 days, the tumors reached an
injectable size and were treated by a single intratumoral
administration of 37 MBq (1.0 mCi) 177Lu−EuDPA/SiO2−NH2
nanoparticles in 100 μL of PBS (group 1) or 37 MBq (1.0 mCi)
177
LuCl3 in 100 μL of PBS (group 2). Control mice (group 3)
received 100 μL of PBS alone. On day 34, after the initial HT-29
injection, the mice were humanely euthanized.
2.13. Biodistribution of 177Lu−EuDPA/SiO2−NH2 Hybrid
Nanoparticles after In Vivo Injection. The HT-29 tumor model
was established by subcutaneous injection of 0.2 mL into the right
ﬂanks of six mice at a concentration of 0.5 × 108 cells/mL
resuspended in a 1:1 mixture of PBS and Matrigel extracellular
matrix preparation (Corning, Oneonta, NY). On day 17, after the
initial HT-29 injection, the mice were randomized into two groups of
three mice each. One group of mice was treated by an intratumoral
administration of 37 MBq (1.0 mCi) 177Lu−EuDPA/SiO2−NH2
nanoparticles in 100 μL of PBS, and a second group was treated by
an intratumoral administration of 37 MBq (1.0 mCi) 177LuCl3 in 100
μL of PBS. At 48 h after treatment, the mice were humanely
euthanized, and organs and blood were collected for determination of
weights. Radioactivity associated with the organs and tissues was
determined by using a model CRC-55tx dose calibrator/well counter
(Capintec, Florham Park, NJ).
8694
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Figure 3. Representative images obtained by scanning electron microscopy (A−C) and EDS mapping analysis (D) of Lu0.5−Eu0.5DPA/SiO2−NH2
nanoparticles.

Table 1. Elemental Quantitative Analysis with the Atomic
and Mass Percentages Obtained by EDS for the Compound
Lu0.5−Eu0.5DPA/SiO2−NH2
element (%)

mass (%)

atomic (%)

std error (%)

C
O
Si
Eu
Lu

32.8
38.9
22.0
3.0
3.3

45.5
40.5
13.2
0.4
0.4

9.9
8.7
3.2
21.3
36.6

in preparation of the 177Lu−EuDPA/SiO2−NH2 radiopharmaceutical. We observed that the compound presented a
morphology similar to EuDPA/SiO2−NH2, with the presence
of small irregular blocks indicating that the introduction of the
lutetium ion in the material did not aﬀect the morphology of
the nanomaterial.
Mapping of the Lu0.5−Eu0.5DPA/SiO2−NH2 compound
using EDS spectroscopy was also performed (Figure 3D).
These results showed that the nanomaterial consists of a higher
amount of Si (13%) among the inorganic elements present. In
addition, we observed that the atomic percentages of europium
and lutetium found within the material were the same (0.4%),
indicating that there was no preference in the introduction of
the metallic ions in the silicon matrix and that the lanthanides
were distributed throughout the uniformly. The identiﬁcation
of all elements is most evident from the analysis of the EDS
spectrum shown in Figure S2. The quantitative representation

Figure 4. Excitation (dotted line) and emission (full line) spectra for
EuDPA (λEx = 283 nm; λEm = 615 nm; blue line) and EuDPA/SiO2−
NH2 (λEx = 279 nm; λEm = 615 nm; red line) compounds obtained at
room temperature. EuDPA was obtained in aqueous solution at 1 ×
10−5 mol/L and EuDPA/SiO2−NH2 in the form of a suspension of
particles in PBS (pH = 7.4; 100 μg/mL).

of mass percentages and atomic percentage for the elements
present in the sample is shown in Table 1.
3.2. Chemical, Thermal, and Compositional Analyses.
For the characterization of the EuDPA/SiO2−NH2 compound,
it was necessary to know in greater detail the main functional
8695
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Table 2. Experimental Values for Radioactive (Arad) and
Nonradioactive (Anrad) Decays, Lifetime (τ), and Quantum
Eﬃciency (η) for EuDPA and EuDPA/SiO2−NH2
compound

Arad (s−1)

Anrad (s−1)

τ (ms)

η (%)

EuDPA
EuDPA/SiO2−NH2

322.6
228.0

1805.0
2297.8

0.47
0.31

15
7

groups present in the dipicolinic acid (H2DPA); for this
reason, the nanoparticles were subjected to FT-IR spectroscopy (Figure S3). The spectrum of the H2DPA (black line)
showed a broad and medium intensity band in the region of
3300−2500 cm−1 due to the O−H stretching of the carboxylic
acid located at the ligand.32 It was also possible to identify the
carbonyl signal (CO) by a single band of narrow and very
pronounced proﬁle located at 1701 cm−1.32 Also, for the
carbonyl signal, the C-O-H out-of-plane bending was
represented by a median intensity signal centered at 1419
cm−1 as well as a signal at 939 cm−1 that was a correlated plane
with the intermolecular hydrogen bonds present in the solid.
The symmetrical C−O stretch with a signal located at 1254
cm−1 32 was also veriﬁed. The presence of the aromatic ring
was present as evidenced by the observation of the CC
stretches of the ring, composed of three signals at 1569, 1538,
and 1462 cm−1, as well as those of the asymmetric and
symmetrical C−H stretches at 2962 and 2871 cm−1,
respectively.32,33
After the identiﬁcation of the main functional groups of the
H2DPA, it was possible to perform a comparative analysis of
the EuDPA metal complex with greater conﬁdence (Figure S3,
blue line). Initially, the asymmetric νASS(COO−) stretch of the
carbonyl (1591 cm−1) was displaced with respect to the CO

Figure 6. Measurement of nanoparticles as determined by %
radioactivity incorporation or speciﬁc activity as a function of the
initial input radioactivity for the synthesis of 177Lu−EuDPA/SiO2−
NH2.

signal from the ligand (1701 cm−1), and this was due to
deprotonation of carbonyl and coordination of this group with
the metal ion, which provides a reduction of the frequency of
molecular vibration and appearance of its band at a
wavenumber lower than that observed for the free ligand.30,31
Analysis of the EuDPA/SiO2−NH2 nanoparticles was also
performed by using the FT-IR spectroscopy technique, as
shown in Figure S3 (red line). This analysis revealed the
presence of a broad and intense band with maximum centering
at 1070 cm−1, which is related to the asymmetric stretching
Si−O−Si from silane-derived groups. The functionalization

Figure 5. Representative confocal ﬂuorescence microscopy images (63× magniﬁcation) of HT-29 cells treated with EuDPA/SiO2−NH2 (λEx = 279
nm; λEm = 500−700 nm), as shown in red (Particle) obtained at concentrations of 10, 100, and 1000 μg/mL in PBS (pH 7.4). The cells were
counterstained with Hoechst 33342 (λEx = 350 nm; λEm = 461 nm), as shown in blue. Colocalization is shown as magenta in the merged images.
Scale bars are 50 μm.
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Figure 7. Coronal views of three-dimensional images after fusion of SPECT maximum intensity projection (MIP) and CT volume rendering
images obtained at (A) 2, (B) 24, and (C) 48 h after injection of 177Lu−EuDPA/SiO2−NH2 nanoparticles intratumorally into athymic nude mice
bearing HT-29 subcutaneous tumors.

Figure 8. Evaluation of biodistribution of (A) 177Lu−EuDPA/SiO2−NH2 (177Lu-NP) nanoparticles and (B) 177LuCl3 (177Lu) following
intratumoral administration in athymic nude mice. Each bar represents the mean ± SEM measurements of three mice.

with −NH2 groups could be identiﬁed by the presence of a
weak band localized at 800 cm−1 due to the N−H vibrations
directed outside the plane.30,31 In addition, a signal in the
centered at 1562 cm−1, referring to the angular deformation
N−H for primary amine, was observed. The EuDPA/SiO2−
NH2 compound also exhibited a low-intensity, maximum
centered signal at 1637 cm−1, which was attributed to the
asymmetric νASS(COO−) stretch of the coordination complex
incorporated into SiO2 nanoparticles.30,31 These results
suggested that the complex was internalized in the rigid silicon
network in its original conformation, which stabilized the
hybrid system by supramolecular interactions.
TGA analysis was also a necessary experimental approach
both to support the characterization of the EuDPA metal
complex and to determine the thermal stability proﬁle of the
EuDPA and EuDPA/SiO2−NH2 compounds. Concerning the

thermal behavior of EuDPA, we observed its decomposition
into two fractions (Figure S4A). In the ﬁrst thermal event, we
observed the elimination of 14% mass in the temperature range
between 30 and 150 °C occurring in two stages, which was
attributed to the removal of seven molecules of water,
hydration, and coordination, present in the coordination
complex. The second heat event was related to the organic
part of the DPA2− coordinate ligand that was eliminated in
three steps, totaling 45% of mass loss in the temperature range
between 150 and 800 °C, giving the compound two ligands
coordinated to the ion metallic. Thus, the chemical
composition of the synthesized complex revealed good
agreement with the theoretically proposed structure Eu(DPA)2(3H2O)]·4H2O,20 as shown in Table S1.
TGA analysis for the EuDPA/SiO2−NH2 nanoparticles was
performed between the 25 and 600 °C regions, as shown in
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(Figure 3; dotted blue line). This diﬀerence is likely related to
the organization of the EuDPA complex, which was
immobilized in the solid state in the form of EuDPA/SiO2−
NH2 nanoparticles. The emission spectrum for the EuDPA/
SiO2−NH2 had the same spectral proﬁle as that presented for
the EuDPA (Figure 4; solid blue line), indicating that the
complex incorporated in the hybrid network conferred the
same point symmetry around the ion in relation to the free
coordination complex. The comparison between the excitation
(λEm = 615 nm) and emission (λEx = 283 nm) spectra between
the EuDPA/SiO2−NH2 (blue lines) and Lu0.5−Eu0.5DPA/
SiO2−NH2 (red lines) was also performed, as shown in Figure
S5. We observed that the excitation and emission spectral
patterns did not change, indicating that the introduction of
lutetium did not cause changes in the chemical environment of
the EuDPA complex within the hybrid compound.
The exponential decays for the 5D0 emitter state were
determined from the exponential decay curve of the EuDPA
and EuDPA/SiO2−NH2 compounds (Figures S6A and S6B).
The curves of both materials presented a monoexponential
proﬁle, indicating the existence of only one emitter metal site
for each system. It was also observed that the EuDPA
compound (Figure S6B) showed a low quantum emission
eﬃciency in relation to the usual complexes of europium,35
equal to 18%, that is associated with a high nonradiative decay
(Anrad = 340.5 s−1). In addition, the compound had a low
lifetime rate (τ = 0.47 ms) that contributed to a quantum
emission eﬃciency. This photoluminescent parameter can be
explained by the presence of energy states from the O−H
oscillators of the water, which is resonant to the 5D0 emitter
state of Eu3+, promoting the deactivation of the luminescence.
Consequently, this eﬀect resulted in a low quantum emission
eﬃciency when compared to similar results in the literature by
using other solvents.20,36
The analysis of exponential decay curves for the EuDPA/
SiO2−NH2 also presented a low value for the radiative decay
rate (Arad = 228.0 s−1), while the value for the nonradiative
decay was high (Anrad = 2297.8 s−1). This fact, combined with a
reduction in lifetime (τ = 0.31 ms), when applying the
radiative decay curve of Figure S6B, indicated a recovery of
quantum eﬃciency of emission equal to 7%. The experimental
values for the radiative (Arad) and nonradiative (Anrad) decays
and quantum emission (η) for EuDPA and EuDPA/SiO2−
NH2 are presented in Table 2.
3.4. Fluorescence Microscopy Imaging of the HT-29
Cell Line. The EuDPA/SiO2−NH2 nanoparticles were
analyzed for cellular uptake by using confocal microscopy
experiments. In this approach, the particle internalization was
examined in HT-29 cells at concentrations 10, 100, and 1000
μg/mL after a 24 h incubation period.
As shown in Figure 5, we observed that the nanoparticles
showed good uptake into HT-29 cells in vitro, with no
indication of any morphological changes. Strong cytoplasmic
ﬂuorescence could be observed, represented by the accumulation of luminescent particles. This evidence of uptake
suggested that the EuDPA/SiO2−NH2 nanoparticles are
promising in the composition of luminescent biomarkers. In
addition, the cytotoxicity of EuDPA/SiO2−NH2 was tested on
HT-29 cells by using an XTT assay to assess the
biocompatibility of the nanoparticles. The assays performed
revealed that cellular viability was not signiﬁcantly aﬀected by
the nanoparticles at the concentrations tested (Figure S7) after
treatment for 24 or 48 h.

Figure 9. Evaluation of the therapeutic potential of the 177Lu−
EuDPA/SiO2−NH2 nanoparticles (177Lu-NP) by measuring tumor
volume as a function of time after intratumoral administration,
compared to treatment with EuDPA/SiO2−NH2 nanoparticles (NP)
or with a negative control (PBS). Each bar represents the mean ±
SEM measurements of ﬁve mice. *P < 0.05 compared to 177Lu-NP.

Figure S4B. We observed that the compound showed two mass
events up to the production of waste from the elimination of
25% of the starting mass of the compound. It is important to
note that the thermogram found for EuDPA/SiO2−NH2
resembles that described in the literature for SiO2 nanoparticles.34 In addition, these results were found to agree with
reported data, in which compounds derived from SiO2
nanoparticles have the percentage of remaining mass increased
with the addition of the other components.
3.3. Spectroscopic Properties. The optical behavior of
the EuDPA and EuDPA/SiO2−NH2 compounds was analyzed
by using excitation, emission spectra, and lifetime analysis. The
excitation spectrum for the EuDPA complex, obtained by
monitoring λEm = 615 nm (Figure 4; dotted blue line),
presented two bands in the region between 240 and 310 nm,
with a maximum centered at 283 nm referring to the π → π*
transition of the DPA2− ligand. It was also possible to observe
the presence of a lower intensity signal centered at 395 nm,
which was related to the 5F0 → 5L6 transition of the Eu3+ ion.
The emission spectrum for EuDPA, using λEx = 283 nm
(Figure 3, solid blue line), revealed the transitions 5D0 → 7FJ
(where J = 0, 1, 2, 3, and 4) typically related to the 4f6
conﬁguration of the Eu3+ ion. Additional analysis of the
emission spectrum also demonstrated the absence of emission
bands from the ligand, indicating that the ligand−metal energy
conversion happened eﬃciently (i.e., antenna eﬀect). In
addition, the spectrum revealed the presence of the 5D0 →
7
F0 transition, which indicates the constraint of the point
symmetry surrounding the ion for the representations Cn, Cnv,
and Cs. It is important to note that the emission proﬁle for the
EuDPA compound was analogous to that reported previously
in the literature.20
The photoluminescence analysis for the EuDPA/SiO2−NH2
compound was also evaluated by its excitation spectra (Figure
4, dotted red line) and emission (Figure 4, solid red line). The
excitation spectrum, obtained by monitoring λEm = 615 nm,
revealed the presence of two bands in the region between 240
and 310 nm, with a maximum centered at 279 nm referring to
the π → π* transition of the DPA2− ligand, although with a
slightly diﬀerent proﬁle from the observed for the EuDPA
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3.5. Radioincoporation of 177Lu into the Luminescent
Nanoparticle. The EuDPA/SiO2−NH2 nanoparticle was next
used as a carrier for incorporating the 177Lu radioisotope as a
constituent (177Lu−EuDPA/SiO2−NH2). The strategy employed was based on the incorporation via the one-pot
radioisotope method in the formation of a hybrid silica
nanoparticle material. To quantify the incorporation percentage of 177Lu, we determined the ratio of the amount of
radioactivity between the compound before and after the
177
Lu−EuDPA/SiO2−NH2 synthesis.
For this assessment, the amount of radioisotope added to
the reaction was varied to obtain the best radioincorporation
conditions. The introduction of higher initial amounts of
177
LuCl3 ranging from 0.109 to 814 MBq (2.94 to 22 mCi)
into the reaction mixture resulted in increasing incorporation
into 177Lu−EuDPA/SiO2−NH2 nanoparticles ranging from
60% to 93% (Figure 6). Based on the incorporation of 177Lu
into the EuDPA/SiO2-NH2 nanoparticles, the values for the
speciﬁc activities of the material (deﬁned as the ratio of
radioactivity to the unit mass) were determined. Using a
calculation of the synthesis of EuDPA/SiO2−NH2 particles
that generated a mass equal to 1.75 ± 0.50 mg, we found that
the log values of speciﬁc activities for the compound showed a
linear relationship to the amount of initial (input) radioactivity
(Figure 6).
3.6. Cellular Uptake of 177Lu−EuDPA/SiO2−NH2. The
uptake of radiolabeled nanoparticles by HT-29 cells was
measured by the amount of radioactivity incorporated after
treatment with the 177Lu-radiolabeled nanoparticles. As shown
in Figure S8A, the relationship between the incubation time
and the uptake of the 177Lu−EuDPA/SiO2−NH2 nanoparticles
was determined. We observed that there was a rapid increase in
the incorporation of radioactivity that was maximal at 28.1%
after 1 h. This accumulation was followed by a slower loss of
radioactivity over time to 10.8% after 24 h of incubation. A
dose response curve associated with the uptake at 24 h of the
177
Lu−EuDPA/SiO2−NH2 nanoparticles was also determined
(Figure S8B). As the concentration of 177Lu−EuDPA/SiO2−
NH2 increased, there was a concomitant increase in % binding
and uptake as measured by radioactivity associate with the HT29 cells that demonstrated a maximum uptake at ∼16%.
3.7. In Vivo SPECT Imaging Experiments. In a
preclinical study to understand the biodistribution of the
radiolabeled nanoparticles, SPECT/CT imaging was used for
in vivo detection. In this experiment, 74 MBq (2.0 mCi)
177
Lu−EuDPA/SiO2−NH2 was injected intratumorally into
athymic nude mice bearing subcutaneous HT-29 tumors.
Subsequently, SPECT/CT images were acquired at (A) 2 h,
(B) 24 h, and (C) 48 h after administration. As shown in
Figure 7, visible accumulation was detected at 2 h in the
subcutaneous HT-29 tumor on the left ﬂank of a nude mouse,
which remained present with a similar SPECT signal pattern
for the or localization at 24 and 28 h after injection of 177Lu−
EuDPA/SiO2−NH2. These results suggest that, once injected,
there is little subsequent diﬀusion away from the tumor site. As
a control, free 177LuCl3 injected intravenously into a mouse did
not accumulate in the tumor, and there was no visible signal by
SPECT/CT imaging (data not shown).
Immediately following the SPECT/CT imaging at 48 h, the
animals were euthanized, and selected organs were dissected
for further analyses. The radioactivity of the tissue samples was
measured by using a well counter and expressed as % injected
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dose/g tissue weight. The in vivo biodistribution results of the
dissection analysis are summarized in Figure 8. Similar to the
results observed in the SPECT images, most of the
radioactivity in mice treated with 177Lu−EuDPA/SiO2−NH2
was found in the tumor (>70%), with limited radioactivity in
the other organs measured (Figure 7A). In contrast, a control
mouse injected with free 177LuCl3 intratumorally showed
radioactivity in the liver, spleen, and stomach/intestine as well
and kidney and lung. These results support the retention of
radioactivity at the tumor site by using 177Lu−EuDPA/SiO2−
NH2 nanoparticles and their potential use as an imaging agent.
3.8. Evaluation of Therapeutic Potential. A subcutaneous mouse model of colorectal cancer was used to
investigate the therapeutic potential of the 177Lu−EuDPA/
SiO2−NH2 nanoparticles. For this approach, athymic nude
mice were injected subcutaneously with 1 × 107 HT-29 cells.
At 16 days after the initial injection, when the tumors reached
∼500 mm3, the mice in one group (n = 5) were treated with a
single intratumoral injection of 177Lu−EuDPA/SiO2−NH2.
The second group of mice (n = 5) was treated with a single
intratumoral injection of EuDPA/SiO2−NH2 as a negative
control; the third group (n = 5) was treated with a single
intratumoral injection of PBS as a no treatment control.
As shown in Figure 9, the treatment of mice with 177Lu−
EuDPA/SiO2−NH2 resulted in signiﬁcant inhibition of tumor
growth. In comparison, the treatment of mice with a
nonradioactive control EuDPA/SiO2−NH2 did not aﬀect
tumor growth compared to mice receiving PBS treatment
alone. Tumor growth in these groups continues exponentially
until the experiment was terminated on day 33. Biodistribution
and dosimetry studies of therapeutic biomolecules radiolabeled
with 177Lu have been performed.37,38 Based on these ﬁndings,
future in vivo studies will need to be performed to assess the
biosafety and determine the radiation-absorbed doses from
177
Lu−EuDPA/SiO2−NH2 administration.
As a proof of principle for preclinical application, we
performed a direct intratumoral injection of 177Lu−EuDPA/
SiO2−NH2 nanoparticles. This locoregional approach could
potentially be used as an alternative to the systemic
administration of drugs for the treatment of localized tumors.
However, in the case of metastatic disease, intratumoral
nanoparticle delivery would not be feasible. Instead, a targeted
distribution would be necessary to reach distant sites. One
approach to the delivery of nanoparticles to a tumor site has
consisted of passive targeting, mainly through the enhanced
permeability and retention (EPR) eﬀect after systemic
administration.39 Despite clinical eﬀorts to exploit passive
targeting approaches for drug delivery to cancer cells, only
limited success has been achieved, likely due to nonselective
targeting eﬃciency. Therefore, future directions to improve
77
Lu−EuDPA/SiO2−NH2 nanoparticles will include active
targeting strategies40 mediated by incorporating biological
ligands (i.e., proteins, polysaccharides, aptamers, peptides,
small molecules, etc.) with a high aﬃnity toward cancer cell
surface receptors.

4. CONCLUSIONS
In this study, we synthesized the compounds EuDPA and
EuDPA/SiO2−NH2 and characterized them by SEM, FT-IR,
TGA, and luminescence, which determined their chemical,
morphological, and optical properties. Radiolabeling of
EuDPA/SiO2−NH2 with 177Lu showed eﬃcient incorporation
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into the ﬁnal compound for use in SPECT imaging and
radiotherapy using an HT-29 colon cancer preclinical model.
These results support the use of 177Lu−EuDPA/SiO2−NH2
particles for imaging tumors and demonstrate their therapeutic
potential for treating colorectal tumors in vivo.
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